05 Apr 2009 05:00 AM
Synexus Recruits Highest Number Of Patients For Successful JUPITER Study
Manchester-based Synexus, a global leader in the recruitment of patients to its own
research centres, recruited 2,200 of the 17,802 patients who took part in the recent
JUPITER trial presented on Monday 30th March at the ACC*and published in the Lancet.
It was the most successful source of patient recruitment providing 13% of participants to
just 1% of the 1315 sites taking part in the study.
Commenting on Synexus role in the JUPITER trial, Michael Fort, CEO said: "Our success in recruiting patients quickly and efficiently is increasingly well known across a range of therapies…
Commenting on Synexus role in the JUPITER trial, Michael Fort, CEO said: "Our success in recruiting patients quickly and efficiently is increasingly well known across a range of therapies…
